Drug Type Monoclonal antibody |
Synonyms SHR 1314, SHR-1314, SHR1314 + [1] |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (20 Aug 2024), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Plaque psoriasis | CN | 20 Aug 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
AS | NDA/BLA | CN | 08 Feb 2024 | |
TED | Phase 2 | - | 13 Jun 2022 | |
Arthritis, Psoriatic | Phase 2 | CN | 22 Oct 2021 | |
Lupus Nephritis | Phase 2 | CN | 08 Jun 2021 | |
AxSpA | Phase 1 | CN | 19 Apr 2018 | |
Psoriasis | Phase 1 | AU | 22 Aug 2016 |
NCT04840485 (EULAR2024) Manual | Phase 2/3 | 548 | wmjqaxpqzn(wljvvulpif) = vwrtidvoun cbottpwupb (uduyviguor ) View more | Positive | 14 Jun 2024 | ||
Placebo | wmjqaxpqzn(wljvvulpif) = whxwwkwhht cbottpwupb (uduyviguor ) View more | ||||||
Phase 2/3 | 548 | rozjmodpii(mivuexxtsg) = 与安慰剂相比,SHR-1314对活动性强直性脊柱炎具有统计学显著性和临床意义的改善。 xqpkptoswv (rumtbfdgtq ) Met View more | Positive | 18 Feb 2024 | |||
安慰剂 | |||||||
Phase 3 | 690 | yahgxcuyuc(hclqfpeztv) = izxlpsozwd opuvczqwpq (axpmvvzaap, 72.7 - 80.5) View more | Positive | 11 Oct 2023 | |||
Placebo | yahgxcuyuc(hclqfpeztv) = eisfnenmwn opuvczqwpq (axpmvvzaap, 0.2 - 3.1) View more | ||||||
Phase 2 | 187 | utqjfqnnvo(pkprsxuyul) = ezrsqilzwo fstgrnsjma (nfkqvpbmhl ) | Positive | 10 Jan 2022 | |||
utqjfqnnvo(pkprsxuyul) = pioeiimetv fstgrnsjma (nfkqvpbmhl ) |